Every recruitment ad for a clinical trial has to pass IRB review before it runs, and social media ads add a second review by Meta on top. This guide covers what FDA guidance says an ad may and may not include, how payment can be described, what counts as advertising, and how to get a set of digital ads approved the first time.
Yes. FDA guidance treats advertising for study participants as the start of the informed consent and subject selection process, so the IRB reviews recruitment materials before they are used. That includes social media and search ads, not only flyers. The IRB checks that an ad is accurate, is not coercive, and does not promise benefits beyond what the consent document and protocol describe. Your own IRB's written policy always takes precedence over any general guidance, including this page.
An ad is the first thing a potential participant learns about a study, often before anyone from the study team has spoken to them. If the ad overstates benefits, plays down risks, or leans on payment, it shapes how the person sees the study before informed consent begins. That is why FDA's guidance on recruiting study subjects says IRBs should review the methods and materials investigators propose for recruitment, and why it describes direct advertising to participants as acceptable in itself but in need of review.
For federally funded research under the Common Rule (45 CFR 46), IRBs are also responsible for making sure that the selection of subjects is equitable. Where and how a study is advertised affects who hears about it, so recruitment methods are part of that review.
In practice, the IRB is looking for three things in an ad:
FDA's guidance notes that this is especially important when a study may enroll people who are vulnerable to undue influence.
FDA guidance gives a short list of what an ad can contain and a short list of what it should not. Most institutional IRB policies are built on these two lists, sometimes with stricter local rules added.
FDA does not require all six. Ads should be limited to what a person needs to decide whether they are eligible and interested. Source: FDA, Recruiting Study Subjects.
Many institutions also prohibit exculpatory language and coercive wording. Source: FDA guidance; see also institutional policies such as the University of Utah IRB.
A fictional sleep study, written two ways. The first version breaks several of the rules above. The second says the same thing in a way an IRB and Meta can both approve.
Riverside University and this study are fictional, used for illustration only. More samples are in the clinical trial advertising examples.
Payment is the area where IRB policies differ the most. FDA guidance says an ad may state that participants will be paid, but should not emphasize the payment or the amount, for example by printing it in larger or bold type. What that means in practice varies by institution:
The safest default for digital ads is a single plain sentence in the body text, never in the headline or the image. That also keeps the ad clear of platform reviewers, who look harder at ads that lead with money.
If it is aimed at potential participants and invites them to take part, plan on submitting it. FDA guidance names newspapers, radio, TV, bulletin boards, posters, and flyers, and the same reasoning applies to digital channels.
Facebook and Instagram ads, including every combination of image, headline, and body text you plan to run.
Vertical versions of each ad for Instagram and Facebook Stories and Reels, including any on-screen text.
The page or form the ad links to, including the wording of self-screening questions.
Reviewed in final form, including layout, type size, and images.
Reviewed as the final recording. FDA guidance allows the script to be approved first, then the final recording through expedited review.
What staff say on screening calls, and recruitment emails or texts sent to potential participants.
FDA guidance says IRB review is not required for internet listings of clinical trials that contain only basic information, such as the title, purpose, protocol summary, basic eligibility criteria, site locations, and how to contact the site. A standard ClinicalTrials.gov record fits that description. Communications aimed at health professionals, such as "dear doctor" letters, and news stories are also outside the scope of the guidance. If a listing adds more descriptive or promotional text, treat it as an ad.
The rules are the same as for a flyer. What changes is the volume: a digital campaign may run several headlines, images, and text versions at once, and the IRB needs to see each one.
FDA guidance asks IRBs to review printed ads in final form, including type size and visual effects. For a Facebook or Instagram campaign, the equivalent is every combination of image, headline, body text, and call-to-action button, shown as it will actually appear. Submitting a single "sample" ad and then running five versions is one of the most common ways teams end up back in front of the IRB with an amendment.
The IRB will want to see where the ad leads. If it links to a REDCap survey, a Qualtrics form, or a landing page, include screenshots or the full text of that page and its screening questions. If the screener collects contact information, be ready to explain how that information is stored and who sees it. FDA's guidance makes the same point about phone screening: a general promise that confidentiality will be maintained is not enough.
Social ads collect public comments. Your IRB may ask how you will handle comments where people share personal health details or ask medical questions. Decide in advance who monitors the ad, how quickly comments are hidden or answered, and what the standard reply says. A short line pointing people to the study contact is usually enough.
Some IRBs ask how the audience will be selected. Health-condition targeting is not available on Meta, so describe what is actually used: location radius around the site, age range, and language. That description also helps the IRB with its equitable selection review.
FDA guidance recommends that ads be reviewed as part of the initial review package. Ads created after the study is approved can be submitted as an amendment. When an ad closely matches the approved consent document, FDA guidance notes it can be reviewed through expedited procedures; if not, it may need review at a convened IRB meeting. Including the full ad set up front, before the protocol is approved, is usually the fastest route.
Any change after approval, such as a new headline, a different image, or an edited eligibility line, goes back for review before it runs. Format-only adjustments a platform requires, such as cropping an image to a new size, are worth confirming with your IRB office, since policies differ on whether they need an amendment.
Once the IRB approves an ad, Meta still reviews it under its own health advertising rules, and those rules are not the same as the IRB's.
If a platform rejects an ad after IRB approval, any rewording has to go back to the IRB. The way to avoid that loop is to write the ad for both reviews before the IRB sees it. The compliance page covers how TrialFill handles both, and clinical trial advertising shows a full example of a compliant ad.
Yes. FDA guidance says the IRB should review the methods and materials investigators propose for recruiting subjects, because advertising is the start of the informed consent and subject selection process. That covers paid social and search ads, flyers, posters, radio and video spots, landing pages, and phone screening scripts. Ads are best submitted with the initial review package; ads added later are reviewed as amendments.
FDA guidance lists six items an ad may include when appropriately worded: the name and address of the investigator or research facility, the condition under study or the purpose of the research, a summary of eligibility criteria, a brief list of participation benefits if any, the time or other commitment required, and the location of the research with a contact person or office. FDA does not require all six. Ads should be limited to what a person needs to decide whether they are eligible and interested.
Under FDA guidance, ads should not claim or imply that the investigational product is safe or effective, or equivalent or superior to other treatments. They should not call it a "new treatment," "new medication," or "new drug" without saying it is investigational, should not promise "free medical treatment" when the only meaning is that participation costs nothing, and should not emphasize payment with larger or bold type. Ads also should not promise a favorable outcome or benefits beyond what the consent document and protocol describe.
Yes, in most cases. FDA guidance says an ad may state that participants will be paid, but should not emphasize the payment, for example by showing the amount in larger or bold type. Some IRBs allow a dollar amount and others only allow a statement that compensation is offered, so follow your own IRB's policy.
FDA guidance says IRB review is not required for listings of clinical trials on the internet when the listing is limited to basic information such as the title, purpose, protocol summary, basic eligibility criteria, study site locations, and how to contact the site. If a listing adds more descriptive information, IRB review may still be appropriate.
Generally, yes. FDA guidance asks IRBs to review the final copy of printed ads, including type size and visual effects, and the final version of recorded audio and video. For digital campaigns that means each headline, body text, and image combination, plus the landing page or screener it links to. Submitting every variation together in one packet is the fastest way through.
No. IRB approval and platform approval are separate. Meta enforces its own health advertising policies, and an IRB-approved ad can still be rejected, for example for wording that implies the viewer has a health condition. Build the ad to satisfy both before it goes to the IRB, so the approved version is also the version the platform accepts.
This page summarizes public guidance. It is not legal or regulatory advice, and your IRB's written policies always take precedence.
TrialFill writes recruitment ads from your approved materials and delivers the full set as an IRB-ready packet, written for Meta's health advertising policies from the start. Tell us about your study and you'll have a recruitment plan back within one business day.
Start a Study